Recro Pharma – $15 Million Follow-On

New York – August 30, 2016 – Cooley advised the underwriters on Recro Pharma's $14.9 million follow-on offering of 1,986,666 shares of common stock.

Recro Pharma, which trades on The NASDAQ Capital Market as "REPH," is a specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain.

Piper Jaffray & Co. acted as sole book-running manager for the offering and Janney Montgomery Scott acted as co-manager.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.